Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells (Q31719328)

3 July 2017

title

Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells (English)

1 reference

clear cell adenocarcinoma

3 July 2017

1 reference

1 reference

ovarian clear cell adenocarcinoma

inferred from title

1 reference

1 reference

Ohta I

1

1 reference

3 July 2017

Gorai I

2

1 reference

3 July 2017

Miyamoto Y

3

1 reference

3 July 2017

Yang J

4

1 reference

3 July 2017

Zheng JH

5

1 reference

3 July 2017

Kawata N

6

1 reference

3 July 2017

Hirahara F

7

1 reference

3 July 2017

Shirotake S

8

1 reference

3 July 2017

publication date

1 January 2001

1 reference

3 July 2017

language of work or name

0 references

1 reference

3 July 2017

volume

162

1 reference

3 July 2017

issue

1

1 reference

3 July 2017

page(s)

39-48

1 reference

Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties

3 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

Second-line chemotherapy for recurrent carcinoma of the ovary.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

Epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

Prediction of response to drug therapy of cancer. A review of in vitro assays

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

1 reference

7 January 2021

Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration--time product

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

In vitro measurement of chemosensitivity of human small cell lung and gastric cancer cell lines toward cell cycle phase-nonspecific agents under the clinically equivalent area under the curve

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

Cell biological markers of drug resistance in ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

The role of detoxifying systems in resistance of tumor cells to cisplatin and adriamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

Molecular effects of paclitaxel: myths and reality (a critical review).

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell Lines in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: A Phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2800%2900605-4

7 January 2021

10.1016/S0304-3835(00)00605-4

Identifiers

DOI

1 reference

3 July 2017

1 reference